Simon Janes Antoine van Sint Fiet Giovanni Pintaldi

Slides:



Advertisements
Similar presentations
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Advertisements

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Part A/Module A1/Session 4 Part A: Module A1 Session 4 Comprehensive Care for People Living with HIV/AIDS (PLHA)
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
ICTC Team Training 1 ICTC: Roles, Referrals and Linkages.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.
PROJECT INSPIRE NYC Hep C Taskforce Meeting May 20,
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
OPIOID SUBSTITUTION THERAPY
Integrated Health Programs for Women and Children: Lessons from the Field Dr. Ambrose Misore Project Director, APHIA II Western, PATH’s Kenya Country Program.
1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.
Health Care Reform Primary Care and Behavioral Health Integration John O’Brien Senior Advisor on Health Financing SAMHSA.
NURSETRI, Nursing role in HIV care : an overview Jane Bruton Clinical Research Nurse.
STATE OF THE STATE SHELLEY LUCAS HIV/STD PREVENTION & CARE BRANCH DEPT OF STATE HEALTH SERVICES AUGUST 3, 2015.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
National Strategy for Quality Improvement in Health Care June 15, 2011 Kana Enomoto Director Office of Policy, Planning, and Innovation.
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
The Hepatitis C Treatment Access Crisis Ryan Clary Executive Director May 22, 2015.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
AIDS 2014 Workshop on increasing access to TB services as part of integrated care for people who inject drugs Integrating TB services.
Prevention, Treatment and Care of Hepatitis C among People Who Inject Drugs Jason Grebely, PhD Senior Lecturer Viral Hepatitis Clinical Research Program.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
“Measuring the Units” Alcohol liaison services (ALS) Louise Poley Consultant Nurse in Substance Misuse Cardiff and Vale University Health Board.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
The Role of Psychology Within Addiction Services Dr Mette Kreis, Clinical Psychologist Prison Addiction Clinical Psychology Service, NHS Forth Valley Dr.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Integrated services for people who use drugs in vertical health care systems: challenges and solutions Kostyantyn Dumchev, MD, MPH July 19, st.
#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.
HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities
LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA
Deadly trio: mental health – HIV - drugs
Key Population Community taking the Lead.
How differentiated care supports “Tx all” and Dr
IAS Satellite Session 25th July 2017 Daniel Were, PhD
Addressing Viral Hepatitis
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Gaps in the cascade of care in two high prevalence settings in Zimbabwe and Malawi Nolwenn Conan1, Cyrus Paye2, Erica Simons2, Abraham Mapfumo3, Tsitsi.
Fabienne Hariga Senior Adviser, HIV/AIDS Section
Differentiated Service Delivery: Innovating for Impact
Hepatitis C Allies of Philadelphia August 2, 2017
2017 Key Considerations for adolescents and children & Key populations
Continuum of HIV Care, Treatment, and Prevention
Current harm reduction program at outreach
Marie P. Bresnahan, MPH, Mary M
BY MAELO DAVID BUMULA SC BUNGOMA COUNTY
Integrating Hepatitis C Treatment in Primary Care
Screening, Brief Intervention and Referral to Treatment
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Documenting barriers to access HCV care and treatment: a peer-led research João Santa Maria, Magda Ferreira, Renato Pinto, Joana Sanches, Álvaro Ávila,
Department of Veterans Affairs
Building Health Systems to Deliver People-centered Health Services
Dr. Muhammad Ajmal Zahid Chairman, Department of Psychiatry,
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Edward Mbizo Sibanda, (MSc) Right to Care
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
Blood borne viral hepatitis action in Wales
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
What existing research and data can tell us
Professor Jack Lambert
Lesson 3: Treatment as Prevention
Public Health Implications
Presentation transcript:

Simon Janes Antoine van Sint Fiet Giovanni Pintaldi “The five pillars of care” An inclusive and equitable medical approach to hepatitis C care in people who inject drugs Simon Janes Antoine van Sint Fiet Giovanni Pintaldi MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Context MSF present in Manipur state in the north-east of India, since 2004 Currently operates two ART centers under public private partnership with NACO, in Churachandpur and Moreh providing care for HIV, (DR)-Tuberculosis (TB), and Hepatitis C virus (HCV) infection HIV and HCV epidemic in Manipur has been driven by the use of intra-venous drugs. MSF India, "The five pillars of care"

Substance Use Disorder Inter-related Morbidities Estimate prevalence HCV infection in India: 1- 1.5%1 Estimated prevalence of HIV infection in: India (2015): 0.26%2 Manipur (2015): 1.22%2 Estimated prevalence's of HIV and HCV in people who inject drugs (PWID’s) in Manipur3: HIV infection: 27.9% - 43.3% HCV infection: 45.5% - 68.4% HIV / HCV co-infection: 21.0 % - 29.2% Substance Use Disorder Tuberculosis Mental Health Illness HIV Hepatitis C Puri,et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL); 2014. National AIDS control Organisation: India HIV Estimations 2015, Technical Report. Solomon, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study; 2014.

Barriers to HCV care for PWID’s Barriers present at multiple levels of “HCV cascade of care” Stigma and discrimination Treatment domain of specialist hospital system Absence of peer and adherence support Separation of treatment from Harm reduction / oral substitution treatment services Cost MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Exclusion Limited treatment with overwhelming demand Complexity of treatment with interferon containing regimens Programmatic desire for good performance resulting in exclusion of patients with multiple co-morbidities Prioritisation of patients with advanced liver disease Concerns of re-infection, poor adherence and poor outcomes in PWID’s MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Inclusion Holistic patient centered approach required, focusing on individualised priorities and not specific diseases Ethical considerations of autonomy, beneficence, non-maleficence, justice and respect for persons have been largely ignored Provides important opportunity for behavioral modification and uptake of harm reduction services Highest burden of incident cases amongst PWID’s Treatment as prevention Improved care for related co-morbidities through increased awareness and development of expertise MSF India, "The five pillars of care"

MSF India, "The five pillars of care"

Psychosocial assessment ASSESSMENT AND PRIORITISATION Medical assessment Clinical assessment Routine baseline blood Screen for: TB /Opportunistic infection Review HIV care HIV Viral Load HCV Viral Load / Genotype APRI: AST platelet ratio index Fibroscan Psychosocial assessment Demographics Social support and coping skills Mental Health Status Depression screening tool: PHQ9 ASSIST questionnaire AUDIT Alcohol use tool Motivation and barriers to treatment Adherence factors Clinical Case Review ASSIST: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) MSF India, "The five pillars of care"

INDIVIDUALISED CARE HIV TB / Opportunistic infection Hepatitis C New patients: existing schedule for pre-treatment and on-going HIV counselling Existing patients: Adherence counselling: second weekly Clinical case review: 4/12 TB / Opportunistic infection Counselling as required Clinical Case review at completion of medical treatment of existing co-infection Hepatitis C Pre-treatment counselling Adherence counselling: 1, 2, 4, 6, 8, 12, wks Clinical case review at completion of HCV treatment Substance Use Disorder Counselling as required OST referral for PWID’s as required Regular counselling with OST Repeat ASSIST / AUDIT Clinical case review: 4/12 Mental Illness Counselling as required Sever illness: psychiatrist referral Individualised counselling plan Repeat PHQ9 at 3/12 Clinical case review: 4/12 Regular medical r/v Adherence: Repeat VL at 3 /12 of counselling Specific TB/OI treatment Regular medical r/v Regular medical r/v Monitor HCV viral load Test of cure at 12 wks Routine medical care. Care for complications of intravenous drug use Psychiatrist review Pharmacotherapy if required MSF India, "The five pillars of care"

Morbidity identified as primary treatment priority CLINICAL CASE REVIEWS 92 Morbidity identified as primary treatment priority HIV 11 TB Opportunistic Infection 1 Hepatitis C 54 Substance Use Disorder 15 Mental Health illness 8 Repeated clinical case review of 31 patients: 18 re-prioritised for HCV treatment RE-PRIORITISATION TO HCV TREATMENT FOLLOWING INITIAL INTERVENTION 3 1 9 5 MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Overall average duration from initial case review to prioritisation for HCV treatment for all types of intervention = 7.5 months Average duration between initial clinical case review and prioritisation for HCV treatment for each initial priority: Substance use disorder: 7.8 months Mental health illness: 5.9 months HIV adherence: 8 months TB / Opportunistic infection: 3.5 months MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Conclusions Through a multi-disciplinary model to assess, prioritise and manage related co-morbidities, the most vulnerable populations can be equitably included in treatment of Hepatitis C There is a requirement for program managers and treatment providers to understand, accept and adapt care models to issues of social function and stigmatisation specific to PWID that currently limit access to treatment including the parallel provision of effective harm reduction services There are sound ethical and scientific justifications for the creation of models of care delivery specifically tailored for the needs of PWID’s MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Acknowledgements We would like to thank the MSF specialist advisors Dr Michiel Lekkerkerker and Dr Krzysztof Herboczek We would like to thank the MSF team in Manipur for their unyielding dedication and hard work. We would like to acknowledge Dr Till Kinkel whose contribution to initial discussions were responsible for a reorientation from an “exclusive” to “inclusive” mentality. We also acknowledge Dr Julian Sheather’s valuable contributions to the ethical considerations MSF India, "The five pillars of care"

MSF India, "The five pillars of care" Thank-you MSF India, "The five pillars of care"